SEOUL, South Korea, May 30, 2021 /PRNewswire/ -- Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., announced on May 26th that it had acquired a 50% stake in RosVivo Therapeutics Inc. ("Rosvivo"), an American new drug developer, for about 5.5 million U.S. dollars. As a...
from PR Newswire: https://ift.tt/3c4ywFl
No comments:
Post a Comment